Literature DB >> 17687644

Anti-estrogenic mechanism of unliganded progesterone receptor isoform B in breast cancer cells.

Ze-Yi Zheng1, Si-Min Zheng, Boon-Huat Bay, Swee-Eng Aw, Valerie C-L Lin.   

Abstract

Over half of breast cancer cases are estrogen-dependent and strategies to combat estrogen-dependent breast cancer have been to either block the activation of estrogen receptor (ER) or diminish the supply of estrogens. Our previous work documented that estrogen-independent expression of progesterone receptor (PR) in MCF-7 cells markedly disrupted the effects of estrogen. In this study, we have developed an adenovirus-mediated gene delivery system to study the specific involvement of PR isoform A (PR-A) and PR-B in the anti-estrogenic effect and its mechanism of action. The results revealed that PR-B, but not PR-A, exhibited distinct anti-estrogenic effect on E2-induced cell growth, gene expression, and ER-ERE interaction in a ligand-independent manner. The anti-estrogenic effect of PR-B was also associated with heightened metabolism and increased cellular uptake of estradiol-17 beta (E2). We have also found that the B-upstream segment of PR-B alone was able to inhibit E2-induced ER-ERE interaction and cellular uptake of E2. Although PR-A alone did not affect E2-induced ER activity, it antagonized the anti-estrogenic effect of PR-B in a concentration-dependent manner. The findings suggest an important mechanism of maintaining a favorable level of ER activity by PR-A and PR-B in estrogen target cells for optimal growth and differentiation. The potential anti-estrogenic mechanism of PR-B may be exploited for breast cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17687644     DOI: 10.1007/s10549-007-9711-8

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  8 in total

1.  Functionality of unliganded VDR in breast cancer cells: repressive action on CYP24 basal transcription.

Authors:  Fatouma Alimirah; Avani Vaishnav; Michael McCormick; Ibtissam Echchgadda; Bandana Chatterjee; Rajendra G Mehta; Xinjian Peng
Journal:  Mol Cell Biochem       Date:  2010-05-04       Impact factor: 3.396

2.  Lysine methylation of progesterone receptor at activation function 1 regulates both ligand-independent activity and ligand sensitivity of the receptor.

Authors:  Hwa Hwa Chung; Siu Kwan Sze; Amanda Rui En Woo; Yang Sun; Kae Hwan Sim; Xue Ming Dong; Valerie C-L Lin
Journal:  J Biol Chem       Date:  2014-01-10       Impact factor: 5.157

Review 3.  Role of epigenetic modifications in luminal breast cancer.

Authors:  Hany A Abdel-Hafiz; Kathryn B Horwitz
Journal:  Epigenomics       Date:  2015-02-17       Impact factor: 4.778

4.  Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients.

Authors:  Thushangi N Pathiraja; Priya B Shetty; Jaroslav Jelinek; Rong He; Ryan Hartmaier; Astrid L Margossian; Susan G Hilsenbeck; Jean-Pierre J Issa; Steffi Oesterreich
Journal:  Clin Cancer Res       Date:  2011-04-01       Impact factor: 12.531

5.  Unliganded progesterone receptor-mediated targeting of an RNA-containing repressive complex silences a subset of hormone-inducible genes.

Authors:  Guillermo Pablo Vicent; A Silvina Nacht; Roser Zaurin; Jofre Font-Mateu; Daniel Soronellas; Francois Le Dily; Diana Reyes; Miguel Beato
Journal:  Genes Dev       Date:  2013-05-15       Impact factor: 11.361

6.  Acetylation at lysine 183 of progesterone receptor by p300 accelerates DNA binding kinetics and transactivation of direct target genes.

Authors:  Hwa Hwa Chung; Siu Kwan Sze; Alvin Shun Long Tay; Valerie C-L Lin
Journal:  J Biol Chem       Date:  2013-12-03       Impact factor: 5.157

7.  High Levels of Progesterone Receptor B in MCF-7 Cells Enable Radical Anti-Tumoral and Anti-Estrogenic Effect of Progestin.

Authors:  Natasa Bajalovic; Yu Zuan Or; Amanda R E Woo; Shi Hao Lee; Valerie C L Lin
Journal:  Biomedicines       Date:  2022-08-02

8.  Comparative actions of progesterone, medroxyprogesterone acetate, drospirenone and nestorone on breast cancer cell migration and invasion.

Authors:  Xiao-Dong Fu; Maria Silvia Giretti; Lorenzo Goglia; Marina Ines Flamini; Angel Matias Sanchez; Chiara Baldacci; Silvia Garibaldi; Regine Sitruk-Ware; Andrea Riccardo Genazzani; Tommaso Simoncini
Journal:  BMC Cancer       Date:  2008-06-09       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.